返回 Agenda
Session 5 Track C: Generics and Biosimilars
Session Chair(s)
Loretta Del Bosco
Director, Regulatory Affairs Quality Assurance Operations
AbbVie Corporation, Canada
Gain an overview of generics and biosimilars from a regulator, industry, and industry consultant perspective. The field of generics continues to evolve and Canada is entering into the new era of biosimilars. What are the challenges? What are the opportunities? How are generics and biosimilars different? Hear from subject matter experts on this exciting and sometimes controversial topic.
Speaker(s)
Speaker
Donald Elrick, PHD
Johnson & Johnson Innovative Medicine, Canada
Head, Regulatory Affairs & Commercial Quality
Policy in the Development of Generics and Biosimilars in Canada
Anne Tomalin, RAC
Tpireg, A Division of Innomar-Strategies Inc., Canada
Speaker
Agnes Klein, MD
Health Canada, Canada
Senior Medical Advisor
Speaker
Dawn Culp
Hikma, United States
VP, Regulatory Affairs